MGC Pharmaceuticals Ltd (LON:MXC) has advised that is has released its 30 June 2023, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange’s Listing Rules.
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic
MGC Pharmaceuticals’ Roby Zomer discusses what the company does, the first import of Psilocybin, highlights from the last quarter and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.
MGC Pharmaceuticals plc (LON:MXC) CEO Roby Zomer joins DirectorsTalk Interviews to discuss the granting of its first import permit for 200g of Psilocybin Raw Mushroom material. In this interview Roby reminds
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced it has been granted its first import permit for 200g
MGC Pharmaceuticals Ltd (LON:MXC), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has provided its Quarterly Activity Report for the three months ending
Early adopter in this space is MGC Pharmaceuticals (ASX:MXC), has positioned itself as a key player in pioneering psychedelic research and development. What a time to be alive. As the clock
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has welcomed the new regulation in Australia making it the first country to
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced the appointment of Mr. Layton Mills as a Non-Executive Director of
MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced that CannEpil®, MGC Pharma’s IMP has now been successfully imported and
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
